# American Vanguard Corp: Form 10-Q for the period ended Jun 30, 2018

- Company: [American Vanguard Corp](/companies/avd.md) (CIK 5981)
- Form: 10-Q
- Filed: 2018-08-06
- Accepted by EDGAR: Aug 6, 2018, 16:06 ET
- Period: 2018-06-30
- Accession: 0001564590-18-019422
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/5981/000156459018019422/avd-10q_20180630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/5981/000156459018019422/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-04-01 to 2018-06-30 | $107.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2018-01-01 to 2018-06-30 | $211.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2018-04-01 to 2018-06-30 | $63.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2018-01-01 to 2018-06-30 | $126.8m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2018-04-01 to 2018-06-30 | $43.3m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2018-01-01 to 2018-06-30 | $84.3m | us-gaap:GrossProfit |
| Operating income | 3 months, 2018-04-01 to 2018-06-30 | $8.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2018-01-01 to 2018-06-30 | $15.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2018-04-01 to 2018-06-30 | $966.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2018-01-01 to 2018-06-30 | $1.8m | us-gaap:InterestExpense |
| Income tax | 3 months, 2018-04-01 to 2018-06-30 | $1.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2018-01-01 to 2018-06-30 | $3.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-04-01 to 2018-06-30 | $5.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2018-01-01 to 2018-06-30 | $10.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-04-01 to 2018-06-30 | $0.19 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2018-01-01 to 2018-06-30 | $0.34 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-04-01 to 2018-06-30 | $0.19 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2018-01-01 to 2018-06-30 | $0.35 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-04-01 to 2018-06-30 | 30,190,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2018-01-01 to 2018-06-30 | 30,113,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2018-01-01 to 2018-06-30 | $3.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 6 months, 2018-01-01 to 2018-06-30 | $1.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2018-06-30 | $7.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-06-30 | $288.5m | us-gaap:AssetsCurrent |
| Total assets | at 2018-06-30 | $562.0m | us-gaap:Assets |
| Current liabilities | at 2018-06-30 | $140.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-06-30 | $241.8m | us-gaap:Liabilities |
| Long-term debt | at 2018-06-30 | $74.3m | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | at 2018-06-30 | $0 | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2018-06-30 | $320.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 36,004 characters.

### FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

### MANAGEMENT OVERVIEW

The Company’s operating results improved in most respects for the three months ended June 30, 2018, as compared to the same period of 2017, with net sales up 37% ($107,046 as compared to $77,905 for the same period of the prior year), net income attributable to American Vanguard up 30% ($5,599 v. $4,304), gross profit up approximately 26% ($43,297 v. $34,335), gross margin down to 40% from 44% of net sales and operating expenses up 26% ($34,718 v. $27,654), but down as a percentage of sales to 32% in 2018 as compared to 36% for the same period of the prior year.

Top line sales growth for the second quarter of 2018 was driven by sales of product lines and businesses acquired in 2017, namely, chlorothalonil, abamectin and paraquat (from an FTC-mandated divestment), horticultural products from OHP, Inc., and multiple products sold into Central America by AgriCenter. Performance of pre-existing products was mixed, with improvements in net sales of Impact (post emergent corn herbicide), Dacthal (on high value crops) and Folex (on cotton), and offsetting decreases in Aztec® corn soil insecticide, Bidrin (on cotton) and NAA (a plant growth regulator). Gross profit decreased from 44% of net sales to 40% of net sales quarter-over-quarter, due largely to a higher volume of sales that generate lower margins and by our distribution businesses (AgriCenter and OHP). Factory performance improved significantly and factory activity fully absorbed cost in the quarter. While rising on an absolute basis by 26%, operating expenses declined as a percentage of sales from 36% in the second quarter of 2017 to 33% in the second quarter of 2018. The improved performance (compared to sales) reflects economies of scale achieved overall notwithstanding increases necessary to manage the newly acquired businesses, continued spending to drive long-term growth in our pre-existing business through product development, marketing and business development activities and somewhat offset by adjustments to deferred consideration associated with the businesses acquired in 2017. Net income for the second quarter rose by $1,295 or 30% as compared to the three months ended June 30, 2017.

The Company’s operating results improved in most respects for the six months ended June 30, 2018, as compared to the same period of 2017, with net sales up 42% ($211,154 compared to $148,578 for the same period of the prior year), net income attributable to American Vanguard up 32% ($10,254 v. $7,756), gross profit up approximately 31% ($84,348 v. $64,419), gross margin down to 40% from 43% of net sales and operating expenses up 30% ($68,418 v. $52,605), but down as a percentage of sales to 32% in 2018, as compared to 35% for the same period of the prior year.

For the six month period ended June 30, 2018 the underlying story is similar. The improvement in net sales for the first half of the year was driven primarily by sales of recently acquired product lines and businesses. Performance of pre-existing products was mixed, with increased sales of herbicides (Impact, Dacthal and bromacil), soil fumigants, Folex (a cotton defoliator) and Counter, offset by declines in Aztec® corn soil insecticide, Thimet (due to a drop in peanut acres) and Bidrin (on cotton). Gross margin decreased from 43% in the first half of 2017 to 40% for the same period in 2018 due to increased sale of lower margin products, including products and distribution businesses acquired in 2017. Factory performance improved in comparison to the same six-month period of 2017 and net factory costs were less than a half percent of sales in 2018, as compared to 4% of sales in 2017. During the first six months of the year, operating expenses rose on an absolute basis, but dropped as a percentage of net sales. While we realized some improved efficiencies in connection with freight, we incurred increased expenses for regulatory studies and higher legal expenses incurred in connection with a lawsuit that the Company brought against the U.S. Environmental Protection Agency (“USEPA”) in the United States Court of Federal Claims arising from USEPA’s issuance of a Stop Sale, Use and Removal Order against the PCNB product line in August 2010. Net income for the first half of 2018 rose by $2,498 or 32% as compared to the six months ended June 30, 2017.

When considering the condensed consolidated balance sheet, as of June 30, 2018, net debt has reduced by $3,228, at June 30, 2018, as compared to December 31, 2017, notwithstanding the need to fund additional working capital for our expanded business. Debt, net of deferred loan fees, at June 30, 2018 and at December 31, 2017 was $74,258 and $77,486, respectively. As of June 30, 2018, the Company had the capacity to borrow $137,047, which was broadly in line with the same time last year (June 2017 borrowing capacity was $143,182).

### RESULTS OF OPERATIONS

### Quarter Ended June 30:

| Net sales: | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Insecticides | $32,665 | $39,442 | $(6,777) | -17% |
| Herbicides/soil fumigants/fungicides | 31,401 | 16,045 | 15,356 | 96% |
| Other, including plant growth regulators | 30,377 | 10,096 | 20,281 | 201% |
| Total crop | 94,443 | 65,583 | 28,860 | 44% |
| Non-crop | 12,603 | 12,322 | 281 | 2% |
|  | $107,046 | $77,905 | $29,141 | 37% |
| Cost of sales: |  |  |  |  |
| Insecticides | $18,936 | $25,281 | $(6,345) | -25% |
| Herbicides/soil fumigants/fungicides | 17,379 | 8,114 | 9,265 | 114% |
| Other, including plant growth regulators | 21,183 | 5,098 | 16,085 | 316% |
| Total crop | 57,498 | 38,493 | 19,005 | 49% |
| Non-crop | 6,251 | 5,077 | 1,174 | 23% |
|  | $63,749 | $43,570 | $20,179 | 46% |
| Gross profit: |  |  |  |  |
| Insecticides | $13,729 | $14,161 | $(432) | -3% |
| Herbicides/soil fumigants/fungicides | 14,022 | 7,931 | 6,091 | 77% |
| Other, including plant growth regulators | 9,194 | 4,998 | 4,196 | 84% |
| Gross profit crop | 36,945 | 27,090 | 9,855 | 36% |
| Gross profit non-crop | 6,352 | 7,245 | (893) | -12% |
|  | $43,297 | $34,335 | $8,962 | 26% |
| Gross margin crop | 39% | 41% |  |  |
| Gross margin non-crop | 50% | 59% |  |  |
| Total gross margin | 40% | 44% |  |  |

| Net sales: | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| US | $64,363 | $55,760 | $8,603 | 15% |
| International | 42,683 | 22,145 | 20,538 | 93% |
|  | $107,046 | $77,905 | $29,141 | 37% |

Across our crop business, net sales of our insecticides group were down approximately 17% to end at $32,665, as compared to $39,442 during the second quarter of 2017. Within this category, net sales of our non-granular insecticides were driven by our cotton insecticide Bidrin® which posted lower sales due to carryover of channel inventory and relatively light pest pressure. Further, net sales of our granular soil insecticides were down approximately 5%. This decline was due to the weaker performance of our corn insecticide Aztec® due to timing of international sales and Thimet®, (used primarily in peanuts and sugar cane) due to a roughly 20% reduction in peanut planted acres in 2018.

Within the group of herbicides/fungicides/fumigants used in crop applications, net sales for the second quarter of 2018 increased by approximately 96% to $31,401 from $16,045 in the comparable period of 2017. Net sales of our herbicide products increased approximately 70%, largely due to the addition of the Paraquat product purchased in June of 2017. Sales of our post-emergent corn herbicide Impact® and Dacthal® for use on a wide variety of high valued vegetable crops showed slight increases relative to the second quarter of 2017.We also enjoyed increased sales of our international products Hyvar® and Krovar®. Our soil fumigants business improved 37% from the prior year’s second quarter, when excessively wet weather in the Western region had inhibited the application of these liquid products. In fungicides, we posted significant sales of chlorothalonil, which was acquired in June 2017.

Within the group of other products (which includes our AgriCenter distribution business, plant growth regulators, molluscicides and tolling activity), net sales increased twofold as compared to the second quarter of 2017. Most of this increase arose from AgriCenter sales into Costa Rica, Nicaragua, Honduras, Panama, and the Dominican Republic. Higher quarterly sales of our Folex® cotton defoliant were offset by a decline in our growth regulator product NAA, which sold earlier in this year than in 2017. Slightly lower sales of our metaldehyde granules were offset by higher revenues from our toll manufacturing during this year’s second quarter.

Our non-crop sales ended the second quarter of 2017 up 2% at $12,603, as compared to $12,322, for the same period of the prior year. This increase was due largely to sales from our OHP horticultural business offset by lower sales of our insecticide products for commercial pest control and mosquito control and lower year-over-year royalty payments for our wholly-owned Envance Technology business.

Our international business performed strongly and increased sales by 93%, ending at $42,683, as compared to $22,145 for the second quarter of the prior year. The main growth drivers were related to the AgriCenter distribution business in Central America, new product sales in Mexico following product line acquisitions in August of 2017. Both business lines contributed strongly to sales growth and overall improvement in gross profit performance. Business in other regions performed in line with our expectations including approximately a 100% increase in sales for our Hyvar and Krovar herbicides.

Our cost of sales for the second quarter of 2018 was $63,749 or 60% of sales. This compared to $43,570 or 56% of sales for the same period of 2017. The increase in cost of sales as a percentage of net sales in 2018 is driven by the impact of the mix change including the effect of acquired products and distribution businesses, which drive high sales but at comparatively lower margins than our pre-existing business. This effect was somewhat offset by our factory activity which improved to the extent that we fully recovered our factory costs for the quarter.

Gross profit for the second quarter of 2018 improved by $8,962, or 26%, to end at $43,297 as compared to $34,335 for the second quarter of 2017. Gross margin percentage ended at 40% in the three months ended June 30, 2018, as compared to 44% in the same period of the prior year. As previously noted, the change in performance is largely driven by the new products and businesses acquired in 2017 and partially offset by our improved factory performance.

Operating expenses increased by $7,064 to $34,718 for the three months ended June 30, 2018, as compared to the same period in 2017. The differences in operating expenses by department are as follows:

|  | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Selling | $10,617 | $6,456 | $4,161 | 64% |
| General and administrative | 9,522 | 10,205 | (683) | -7% |
| Research, product development and regulatory | 7,286 | 5,993 | 1,293 | 22% |
| Freight, delivery and warehousing | 7,293 | 5,000 | 2,293 | 46% |
|  | $34,718 | $27,654 | $7,064 | 26% |

- Selling expenses increased by 64% in the three months ended June 30, 2018 as compared to the same period of the prior year. This is mainly resulted from increased sales activities associated with the newly acquired distribution businesses. We also increased spending on advertising and other marketing costs.
- General and administrative expenses decreased by $683 to end at $9,522 for the three months ended June 30, 2018, as compared to the same period of 2017 in part driven by increased activities associated with acquired products and businesses and more than offset by the quarterly re-assessment of fair value associated with deferred consideration for the new business of $1,468 and decreased estimated short and long term incentive compensation costs.
- Research, product development costs and regulatory expenses increased by $1,293 to end at $7,286 for the three months ended June 30, 2018, as compared to the same period of 2017. The increases came from the addition of the new businesses of AgriCenter and OHP and from increased spending on regulatory and product development studies on our expanded portfolio of products and businesses.
- Freight, delivery and warehousing costs for the three months ended June 30, 2018 were $7,293 or 6.8% of sales as compared to $5,000 or 6.4% of sales for the same period in 2017. The increased cost was associated with the 37% increase in sales recorded in the second quarter of 2018, as compared to the same period of 2017 and the mix of those sales.

Interest costs net of capitalized interest, were $966 in the three months ended June 30, 2018, as compared to $400 in the same period of 2017. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Three months ended June 30, 2018 Average Debt | Interest Expense | Interest Rate | Three months ended June 30, 2017 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit (average) | $100,928 | $878 | 3.5% | $45,193 | $292 | 2.6% |
| Amortization of deferred loan fees | — | 58 | — | — | 63 | — |
| Amortization of other deferred liabilities | — | 52 | — | — | 7 | — |
| Other interest (income) expense | — | (5) | — | — | 49 | — |
| Subtotal | 100,928 | 983 | 3.9% | 45,193 | 411 | 3.6% |
| Capitalized interest | — | (17) | — | — | (11) | — |
| Total | $100,928 | $966 | 3.8% | $45,193 | $400 | 3.5% |

The Company’s average overall debt for the three months ended June 30, 2018 was $100,928, as compared to $45,193 for the three months ended June 30, 2017. During the quarter, we continued to focus on managing our working capital for our expanded business and controlling our usage of revolving debt. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 3.5% for the three months ended June 30, 2018, as compared to 2.6% in 2017.

Income tax expense was $1,748 for the three months ended June 30, 2018, as compared to $1,681 for the comparable period in 2017. The effective tax rate for the quarter was 23.0%, as compared to 26.8% in the same period of the prior year. Furthermore, the effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management. The decrease in effective tax rate is primarily driven by the implementation of the Tax Cuts and Jobs Act and excess tax benefits related to the exercise of stock options.

During the three months ended June 30, 2018 we recognized a loss of $347 on our investment in TyraTech. This compared to a loss of $69 recognized in the comparable period of 2017. This reflected both our increased ownership position and the latest information regarding the forecast for their financial performance for 2018. Furthermore, we recognized a gain in the amount of $46 on our investment in the Hong Kong joint venture which is a 50% owned equity investment. Overall we recorded losses for equity method investments for the three months ended June 30, 2018 of $301.

Non-controlling interest amounted to income of $35 in the three months ended June 30, 2018, as compared to loss of $227 in the same period of the prior year. Non-controlling interest represents the share of net income that is attributable to the minority stockholder of our majority owned subsidiary, Envance.

Our overall net income for the three months ended June 30, 2018 was $5,599 or $0.19 per basic and diluted share, as compared to $4,304 or $0.15 per basic and diluted share in the same period of 2017.

### Six Months Ended June 30:

| Net sales: | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Insecticides | $73,958 | $77,384 | $(3,426) | -4% |
| Herbicides/soil fumigants/fungicides | 63,586 | 36,066 | 27,520 | 76% |
| Other, including plant growth regulators | 48,217 | 13,488 | 34,729 | 257% |
| Total crop | 185,761 | 126,938 | 58,823 | 46% |
| Non-crop | 25,393 | 21,640 | 3,753 | 17% |
| Total net sales | $211,154 | $148,578 | $62,576 | 42% |
| Cost of sales: |  |  |  |  |
| Insecticides | $43,756 | $48,825 | $(5,069) | -10% |
| Herbicides/soil fumigants/fungicides | 36,074 | 18,396 | 17,678 | 96% |
| Other, including plant growth regulators | 34,015 | 6,991 | 27,024 | 387% |
| Total crop | 113,845 | 74,212 | 39,633 | 53% |
| Non-crop | 12,961 | 9,947 | 3,014 | 30% |
| Total cost of sales | $126,806 | $84,159 | $42,647 | 51% |
| Gross profit: |  |  |  |  |
| Insecticides | $30,202 | $28,559 | $1,643 | 6% |
| Herbicides/soil fumigants/fungicides | 27,512 | 17,670 | 9,842 | 56% |
| Other, including plant growth regulators | 14,202 | 6,497 | 7,705 | 119% |
| Gross profit crop | 71,916 | 52,726 | 19,190 | 36% |
| Gross profit non-crop | 12,432 | 11,693 | 739 | 6% |
| Total gross profit | $84,348 | $64,419 | $19,929 | 31% |
| Gross margin crop | 39% | 42% |  |  |
| Gross margin non-crop | 49% | 54% |  |  |
| Total gross margin | 40% | 43% |  |  |

| Net sales: | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| US | $134,178 | $108,004 | $26,174 | 24% |
| International | 76,976 | 40,574 | 36,402 | 90% |
| Total net sales | $211,154 | $148,578 | $62,576 | 42% |

Across our crop business, net sales of our insecticides group declined approximately 4% to end at $73,958, as compared to $77,384 during the six months ended June 30, 2017. Within this category, net sales of our non-granular insecticides were driven by our cotton insecticide Bidrin® which posted decreased sales due to year-over-year reduced cotton acres in the USA, movements in channel inventory levels and light early season foliar pest pressure. This was offset by incremental sales of Abamectin acquired in June 2017. Net sales of our granular soil insecticides were down slightly due to the timing of international sales of the corn insecticide Aztec®; reduced planted acreage in peanuts which trimmed our Thimet® sales; offset by positive performance posted by Counter®, which is largely used for nematode control in corn and sugar beets. Internationally, both our Mocap and Nemacur® brand posted slightly increased year-over-year net sales.

Within the group of herbicides/fungicides/fumigants used in crop applications, net sales for the six months ended June 30, 2018 increased by approximately 76% to $63,586 from $36,066 in the comparable period of 2017. This improved performance was driven by incremental sales of paraquat herbicide and chlorothalonil fungicide, acquired in June 2017. Additionally we saw year-over-year increases in many of our pre-existing products, including herbicides Impact, Dacthal, and bromacil; fungicides such as PCNB; and our soil fumigant business, which benefitted from more favorable weather conditions relative to the prior year.

Within the group of other products (which includes our AgriCenter distribution business, plant growth regulators, molluscicides and tolling activity), net sales were $48,217, up approximately two and a half times, as compared to $13,448 in the first half of 2017. The increase was driven by the addition of our AgriCenter distribution business, higher sales of our Folex® cotton defoliant and for our toll manufacturing activity. These were somewhat offset by lower sales of our growth regulator NAA in fruit applications and for our metaldehyde granules.

Our non-crop sales ended the first half of 2018 with net sales of 25,393 up 17%, as compared to $21,640 for the same period of the prior year. This category benefitted from continued strong sales of our aerial-applied mosquito adulticide Dibrom and the addition of the OHP horticulture business which was acquired in November 2017.

Our first half International sales ended at $76,976, a 90% increase over the $40,574 posted for the first six month of 2017. The main driver of this performance was the addition of the AgriCenter Central American distribution business, which was acquired in November 2017. Additionally, we had new incremental sales attributable to the acquisition of the fungicide Chlorothalonil which was acquired in June 2017. Our pre-existing products also showed increases including Mocap, Nemacur, Counter and bromacil.

Our cost of sales for the first half of 2018 ended at $126,806 or 60% of net sales. This compares to $84,159 or 57% of net sales in the same period of 2017. The increase in cost of sales as a percentage of net sales in 2018 is driven by the impact of the mix change including the effect of acquired products and distribution businesses purchased during 2017. Those businesses drive high sales but at comparatively lower margins, as compared to our pre-existing business. This effect was somewhat offset by our factory activity which improved in 2018 to the extent that we have almost fully recovered our factory costs during the first six months. Net factory costs for 2018 year-to-date amounts to less than one half percent of sales, whereas net factory cost in the same period of 2017 amounted to 4% of sales.

Gross profit for the six months ended June 30, 2018 improved by $19,929, or 31%, to end at $84,348, as compared to $64,419 for the first half of 2017. Gross margin percentage ended at 40% in the first six months of 2018, as compared to 43% in the same period of the prior year. As previously noted, the change in performance is largely driven by the new businesses and products acquired in 2017 which drive strong sales and generally earn lower margins, in comparison to our pre-existing businesses.

Operating expenses increased by $15,813 to $68,418 for the six months ended June 30, 2018, as compared to the same period in 2017. The differences in operating expenses by department are as follows:

|  | 2018 | 2017 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Selling | $20,060 | $13,162 | $6,898 | 52% |
| General and administrative | 20,686 | 17,910 | 2,776 | 15% |
| Research, product development and regulatory | 13,563 | 11,689 | 1,874 | 16% |
| Freight, delivery and warehousing | 14,109 | 9,844 | 4,265 | 43% |
|  | $68,418 | $52,605 | $15,813 | 30% |

- Selling expenses increased by $6,898 to end at $20,060 for the six months ended June 30, 2018, as compared to the same period of 2017. The main driver was an increase in activities from the newly acquired businesses during 2017 and increased spending on advertising for our domestic market.
- General and administrative expenses increased by $2,776 to end at $20,686 for the six months ended June 30, 2018, as compared to the same period of 2017, primarily driven by amortization associated with 2017 acquisitions, the inclusion of the administrative activities of those newly acquired businesses and increased long-term incentive compensation accruals. These increases were somewhat offset by the impact of a quarterly re-assessment of the fair value of liabilities under purchase agreements associated with the 2017 acquisitions.
- Research, product development costs and regulatory expenses increased by $1,874 to end at $13,563 for the six months ended June 30, 2018, as compared to the same period of 2017. The main driver was increased spending on regulatory and product development activities for our expanded portfolio of products and businesses and continued spending on development of our SIMPAS delivery system.
- Freight, delivery and warehousing costs for the six months ended June 30, 2018 were $14,109 or 6.6% of sales as compared to $9,844 or 6.6% of sales for the same period in 2017.

Interest costs net of capitalized interest were $1,803 in the first six months of 2018, as compared to $698 in the same period of 2017. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Six months ended June 30, 2018 Average Debt | Interest Expense | Interest Rate | Six months ended June 30, 2017 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit (average) | $94,934 | $1,577 | 3.3% | $44,705 | $550 | 2.5% |
| Amortization of deferred loan fees | — | 117 | — | — | 125 | — |
| Amortization of other deferred liabilities | — | 154 | — | — | 16 | — |
| Other interest (income) expense | — | (11) | — | — | 56 | — |
| Subtotal | 94,934 | 1,837 | 3.9% | 44,705 | 747 | 3.3% |
| Capitalized interest | — | (34) | — | — | (49) | — |
| Total | $94,934 | $1,803 | 3.8% | $44,705 | $698 | 3.1% |

The Company’s average overall debt for the six months ended June 30, 2018 was $94,934, as compared to $44,705 for the six months ended June 30, 2017. During the period, we continued to focus on our usage of revolving debt, while funding working capital for the newly acquired products and businesses. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 3.3% for the six months ended June 30, 2018, as compared to 2.5% in 2017.

Income tax expense was $3,440 for the six months ended June 30, 2018, as compared to $3,061 for the comparable period in 2017. The effective tax rate for the six months ended June 30, 2018 was 24.4%, as compared to 27.5% in the same period of the prior year. Our effective tax rate decreased due to the implementation of the Tax Cuts and Jobs Act in addition to an increase in excess tax benefits related to stock options. Furthermore, the effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

During the six months ended June 30, 2018 we recognized a loss of $443 on our investment in TyraTech. This compared to a loss of $111 recognized in the comparable period of 2017. This reflected both our increased ownership position and their actual financial performance for 2018. The Company’s investment in TyraTech is included in other assets on the condensed consolidated balance sheets. Furthermore, the Company recognized a loss of $75 in our investment in the Hong Kong joint venture, which is a 50% owned equity investment. Overall, we recorded losses for equity method investments for the six months ended June 30, 2018 of $518.

Non-controlling interest amounted to an income of $85 in the six months ended June 30, 2018, as compared to a loss of $188 in the same period of the prior year. Non-controlling interest represents the share of net income that is attributable to the minority stockholder of our majority owned subsidiary, Envance.

Our overall net income for the six months ended June 30, 2018 was $10,254 or $0.35 per basic and $0.34 per diluted share, as compared to $7,756 or $0.27 per basic and $0.26 per diluted share in the same period of 2017.

### LIQUIDITY AND CAPITAL RESOURCES

The Company generated cash of $3,719 in operating activities during the six months ended June 30, 2018, as compared to $34,117 during the six months ended June 30, 2017. Included in the $3,719 are net income of $10,169, plus non-cash depreciation, amortization of intangibles and other assets and discounted future liabilities, in the amount of $12,031, stock based compensation of $2,778, changes in deferred income taxes of $26 and losses from equity method investments of $518. The total provided net cash inflows of $25,470, as compared to $21,268 for the same period of 2017.

During the first six months of 2018 the Company increased working capital by $19,172, as compared to a reduction of $13,875 during the same period of the prior year. Included in this change: inventories increased by $40,194, driven by our expanded business as we work through the annual industry cycle. Deferred revenue decreased by $7,254, as compared to $2,126 in the same period of 2017, driven by customer decisions regarding product demand, payment timing and our cash incentive Programs. Our accounts payable balances increased by $11,309 driven by increased manufacturing activity, the impact of new business cycles associated with our distribution businesses and compared to $579 in the same period of 2017. Accounts receivables decreased by $5,478 as compared to $20,749 in the same period of 2017, with the change driven primarily by a different mix of domestic crop sales (and associated timing and terms) following the purchases of new products in 2017. In the same period of 2017, accounts receivable decreased by $20,749. Prepaid expenses decreased by $707 and income tax receivable decreased by $271. Accrued Programs increased by

$15,039, as compared to $18,819 in the prior year. Finally, other payables and accrued expenses decreased by $5,151, as compared to $4,256 in the prior year as a result of the incentive compensation accrual.

With regard to our Program accrual, the change primarily reflects our mix of sales and customers in the first half of 2018, as compared to the prior year. The Company accrues Programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th of each year. During the first half of 2018, the Company made accruals for Programs in the amount of $28,808 and made payments in the amount of $13,768. During the first half of 2017, the Company made accruals in the amount of $27,341 and made payments in the amount of $8,522. The increased payments in 2018 relate to certain products acquired in 2017 that have different earnings and payment cycles, as compared to the Company’s legacy products.

Cash used for investing activities was $4,861 for the six months ended June 30, 2018, as compared to $18,505 for the six months ended June 30, 2017. The Company spent $3,230 on fixed assets acquisitions primarily focused on continuing to invest in manufacturing infrastructure, $347 related to additional purchase accounting adjustments related to the AgriCenter business acquired in the fourth quarter of 2017 and $1,978 for the acquisition of the bromacil product line for sales in the USA on June 20, 2018.

The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at June 30, 2018 and December 31, 2017. These are summarized in the following table:

| Long-term indebtedness ($000's) | June 30, 2018 Long-term | December 31, 2017 Long-term |
| --- | ---: | ---: |
| Revolving line of credit | $75,100 | $78,425 |
| Deferred loan fees | (842) | (939) |
| Net long-term debt | $74,258 | $77,486 |

As of June 30, 2017, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company, AMVAC CV and AMVAC BV), as guarantors and/or borrowers, entered into a Third Amendment to Second Amended and Restated Credit Agreement (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and Letter of Credit (“L/C”) issuer. The Credit Agreement is a senior secured lending facility, consisting of a line of credit of up to $250,000, an accordion feature of up to $100,000 and a maturity date of June 30, 2022. The Credit Agreement contains two key financial covenants; namely, borrowers are required to maintain a Consolidated Funded Debt Ratio of no more than 3.25-to-1 and a Consolidated Fixed Charge Covenant Ratio of at least 1.25-to-1. The Company’s borrowing capacity varies with its financial performance, measured in terms of EBITDA, for the trailing twelve month period. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.5%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date.

At June 30, 2018, according to the terms of the Credit Agreement and based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $137,047. This compares to an available borrowing capacity of $143,182 as of June 30, 2017. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for trailing twelve-month period plus proforma basis arising from acquisitions, which has improved, (2) net borrowings, which have increased and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement).

We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

### RECENTLY ISSUED ACCOUNTING GUIDANCE

Please refer to Note 14 in the accompanying Notes to the Condensed Consolidated Financial Statements for recently issued accounting standards.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2017, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2017. However, as of January 1, 2018 we adopted the new revenue recognition standard and the new income tax standard.

## Market risk

As filed, 1,323 characters.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2017 and the Company’s Form 8-K filed with the SEC on or about July 6, 2017.

The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into U.S. Dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.

## Controls and procedures

As filed, 1,056 characters.

As of June 30, 2018, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of June 30, 2018, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

### PART II. OTHER INFORMATION

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

## Risk factors

As filed, 1,219 characters.

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2017, filed on March 14, 2018. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors.

**Tariff Activity –** within recent months, the U.S. and China have imposed a series of retaliatory tariffs against one another in respect of various products, ranging from metals to grains to chemicals. To date, the Company has not been materially, adversely affected by these tariffs. However, it is not always possible to predict which products could be targeted by either nation, nor is it possible to predict the size or duration of any given tariff. It is possible that either the U.S. or China could place tariffs on one or more products that would cause either a disruption in the markets of the Company’s customers or an increase in the Company’s cost of goods which, either individually or in the aggregate, could have a material adverse effect upon the Company’s operations or financial performance.

Filed Aug 6, 2018.
Source: SEC EDGAR, the filing index for accession 0001564590-18-019422. Last ingested by Listed: Nov 11, 2026, 00:16 ET. No prices; not investment advice.
